Full-Time

Director of Quality Systems

Multiple Teams

Deadline 6/1/26
Crinetics Pharmaceuticals

Crinetics Pharmaceuticals

501-1,000 employees

Clinical-stage pharma developing rare endocrine therapies

Compensation Overview

$178k - $223k/yr

+ Discretionary Annual Target Bonus + Stock Options + ESPP + 401k Match

San Diego, CA, USA

In Person

Category
Business & Strategy (1)
Required Skills
Veeva
HACCP
Risk Management
Google Cloud Platform
Requirements
  • Bachelor’s degree or Master’s degree in technical field with a minimum of 12 years of relevant Quality Assurance experience in a biotech/pharmaceutical setting. An equivalent combination of experience and education may be considered.
  • 8 years of supervisory experience.
  • GMP experience working with Contract Manufacturing Organizations (CMOs). GCP/GLP experience working with Contract Research Organizations (CROs) is a plus.
  • Proactive leader of quality and compliance culture.
  • Expert working knowledge and understanding of US and international Good Manufacturing Practice regulations and guidance documents. Additional understanding of Good Clinical Practice, Good Laboratory Practice, and pharmacovigilance regulations is a plus.
  • In-depth understanding of global pharmaceutical regulations and quality systems.
  • Ability to interpret complex regulatory requirements and apply them pragmatically.
  • Strong Quality Risk Management background and understanding of QRM principles and tools.
  • Strong analytical, organizational, and stakeholder communication skills.
  • Skilled in using Quality Management Systems and project management tools (e.g., Veeva, Microsoft Project).
  • Strategic mindset with attention to detail and a continuous improvement orientation.
  • Strong project management skills with ability to manage multiple projects and execute in adherence to timelines.
  • Demonstrates sound analytical and problem-solving abilities to resolve complex issues that involve numerous components.
  • Excellent collaboration, interpersonal, verbal, and written communication skills.
  • Good presentation skills to both internal and external audiences.
  • Able to work on issues where analysis of situations or data require conceptual thinking and in-depth knowledge.
  • Has knowledge and experience using a risk-based approach.
Responsibilities
  • Lead or support QA-related projects, including new system implementations, process optimization, and compliance initiatives.
  • Define project scope, timelines, deliverables, and resource needs.
  • Coordinate cross-functional project teams and ensure milestones are met.
  • Monitor project risks, issues, and performance metrics; escalate as needed.
  • Prepare project status reports and presentations for senior management.
  • Lead After Action Review exercises to promote continuous improvement.
  • Identify, assess, and mitigate quality risks using structured methodologies (e.g., FMEA, HACCP, Risk Matrices).
  • Ownership of GxP Risk Management Program and escalate to enterprise-wide risk management board.
  • Develop and maintain risk management plans and documentation.
  • Facilitate risk review meetings and ensure proactive quality risk communication.
  • Monitor the effectiveness of risk controls and update risk assessments regularly.
  • Monitor global regulatory trends, guidance updates, and enforcement actions from regulatory agencies such as FDA, EMA, MHRA, WHO, and PIC/S.
  • Communicate regulatory updates and risk impact assessments to Quality, Regulatory and other impacted departments.
  • Evaluate impact of emerging regulations on internal quality systems, products, and processes.
  • Support timely revision of SOPs, training, and processes in response to regulatory changes or inspection observations.
  • Identify compliance gaps and improvement opportunities to inform the corporate Quality Plan and/or Inspection Readiness plans.
  • Support inspection-readiness activities and regulatory inspections.
  • Manage and mentor the individuals in the quality systems and compliance teams to continually develop and enhance skills.
  • Foster a Quality culture that values innovation, continuous improvement, and personal accountability
  • Execute other duties and project, as assigned by the Senior Director, Quality Systems.
  • Other duties as assigned
Crinetics Pharmaceuticals

Crinetics Pharmaceuticals

View

Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare endocrine diseases and endocrine-related tumors. Its work centers on creating novel orally administered treatments, with CRN00808 for acromegaly currently in Phase 2 trials. The product approach involves identifying targets in endocrine pathways (often GPCRs), and engineering oral drug candidates that modulate these targets to treat conditions with few existing options. The company differentiates itself by concentrating on rare endocrine disorders and advancing candidates through clinical development, aiming to secure regulatory approvals and then pursue commercialization, often via partnerships or licensing with larger pharma players. Its goal is to provide effective, targeted therapies for patients with unmet endocrine needs and to bring approved medicines to market through disciplined clinical development and external collaborations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Physicians project 20-30% adoption rate, implying $670M-$1B US market opportunity.
  • Billionaire Tom Steyer's Farallon Capital increased stake 20% to 7M shares.
  • Atumelnant advancing to Phase III for Cushing's syndrome expands pipeline beyond acromegaly.

What critics are saying

  • Novo Nordisk's entrenched injectable somatostatin analogs dominate market with superior reimbursement pathways.
  • Cash burn of $326M in 2025 exhausts runway if PALSONIFY revenues miss $62M target.
  • Chief Development Officer departure April 2026 disrupts clinical trial oversight and operations.

What makes Crinetics Pharmaceuticals unique

  • First once-daily oral acromegaly treatment approved by FDA and EU regulators.
  • Rapid onset with sustained efficacy in both treatment-naïve and previously treated patients.
  • Well-tolerated with no serious adverse events across PATHFNDR-1 and PATHFNDR-2 trials.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Crinetics Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Unlimited Paid Time Off

PTO/vacation

Holiday/Vacation not?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

1%
Yahoo Finance
Mar 28th, 2026
Crinetics director sells $181K in shares under pre-scheduled trading plan

Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares of common stock on 12 March 2026, valued at approximately $181,000, according to an SEC Form 4 filing. The sale was executed under a Rule 10b5-1 trading plan adopted on 11 December 2025. The transaction reduced Coelho's direct holdings by 23.47%, from 21,300 to 16,300 shares, worth approximately $595,000. Shares were sold at a weighted average price of $36.15, close to the market price of $36.51 on the transaction date. This marks Coelho's only disclosed open-market sale for the clinical-stage biotechnology company, which develops oral therapeutics for rare endocrine diseases. Crinetics had a market capitalisation of $3.97 billion as of 12 March 2026.

Stock Titan
Mar 23rd, 2026
Crinetics (NASDAQ: CRNX) coo-level executive Jeff Knight to resign by April 10, 2026.

Crinetics (NASDAQ: CRNX) coo-level executive Jeff Knight to resign by April 10, 2026. Filing Impact Filing Sentiment Rhea-AI Filing summary. Crinetics Pharmaceuticals announced that Jeff Knight has decided to resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The company states that he is leaving to pursue another opportunity and that his resignation is not due to any disagreement over operations, policies, or practices. Crinetics plans to reassign all of Mr. Knight's managerial responsibilities and direct reports to other members of its executive leadership team, signaling a redistribution of his duties rather than the creation of a new replacement role at this time. Insights. Senior operating executive departs; duties redistributed internally. The departure of the Chief Development and Operating Officer at Crinetics Pharmaceuticals is notable because it affects leadership over development and operations. The company clarifies he is leaving to pursue another opportunity and explicitly notes no disagreements over corporate matters. All of his responsibilities will shift to other executive leaders, indicating an internal reallocation rather than an immediate external hire. The long-term impact will depend on how smoothly this transition proceeds and whether future disclosures outline any organizational or strategic changes following his exit effective on or about April 10, 2026. 03/23/2026 - 09:04 AM Faq. Why did Jeff Knight resign from Crinetics Pharmaceuticals (CRNX)? Jeff Knight resigned as Chief Development and Operating Officer to pursue another opportunity. The company states his resignation is not related to any disagreement regarding operations, policies, or practices, suggesting a voluntary career move rather than a dispute-driven departure. When will Jeff Knight's resignation from Crinetics Pharmaceuticals (CRNX) become effective? Jeff Knight's resignation as Chief Development and Operating Officer is effective on or about April 10, 2026. Until then, he remains in his role while the company prepares to reassign his responsibilities to other members of its executive leadership team. Did Jeff Knight have any disagreements with Crinetics Pharmaceuticals (CRNX) before resigning? Crinetics Pharmaceuticals states that Jeff Knight's resignation is not related to any disagreement with the company. This includes no disputes regarding operations, policies, or practices, indicating the departure is not tied to reported internal conflict or governance issues. How will Crinetics Pharmaceuticals (CRNX) handle Jeff Knight's responsibilities after his resignation? Crinetics plans to reassign all of Jeff Knight's managerial responsibilities and direct reports to other executive leadership team members. This approach redistributes his development and operating duties internally rather than immediately appointing a direct successor or creating a new standalone role. What executive role did Jeff Knight hold at Crinetics Pharmaceuticals (CRNX)? Jeff Knight served as Chief Development and Operating Officer at Crinetics Pharmaceuticals. This combined role covered leadership over drug development and operational functions, which the company now intends to redistribute among other executives following his effective resignation date in April 2026. Does the resignation announcement for CRNX mention any changes to company strategy? The announcement focuses on Jeff Knight's resignation and the reassignment of his responsibilities. It does not outline specific strategic changes, instead emphasizing that duties will move to other executive leaders and that the departure is not due to disagreements over company operations or policies. Filing exhibits & attachments. 3 documents

Yahoo Finance
Mar 9th, 2026
Crinetics' acromegaly drug PALSONIFY hits $5.4M in Q1 sales, EU approval due in May

Crinetics Pharmaceuticals reported early commercial success for PALSONIFY (paltusotine), its acromegaly treatment, with $5.4 million in first-quarter revenue and over 200 patient starts. The drug, priced at $290,000 annually, has attracted 125-plus unique prescribers across academic and community settings. The company received a positive CHMP recommendation for paltusotine in Europe, with approval expected around May. CFO Tobin Schilke said Crinetics is well funded into 2030 following recent capital raising. The pipeline focuses on novel small-molecule GPCR therapies, including atumelnant advancing to Phase 3 for congenital adrenal hyperplasia and paltusotine entering Phase 3 for carcinoid syndrome. On reimbursement, over half of patients secured coverage through medical exceptions, whilst others receive temporary support through a Quick Start programme.

Yahoo Finance
Feb 27th, 2026
Crinetics Q4 revenue hits $6.2M as PALSONIFY gains 125+ prescribers, atumelnant enters phase II/III trial

Crinetics Pharmaceuticals reported Q4 revenue of $6.2 million, including $5.4 million from PALSONIFY, its first commercial product launched in the US. The company has seen early adoption with over 125 unique prescribers and more than 200 enrollment forms, whilst several major payers have added the drug to formularies with label-aligned prior authorisation. The company announced atumelnant, the first ACTH receptor antagonist tested in humans, will enter a global phase II/III trial in the first half of 2025 for ACTH-dependent Cushing's syndrome. Crinetics used $326.2 million cash in 2025 and, following a January 2026 offering, has approximately $1.4 billion in cash and investments. Management provided 2026 GAAP operating expense guidance of $600–650 million, with funds expected to support operations into 2030.

MarketScreener
Jan 7th, 2026
Crinetics Pharmaceuticals prices $350M public offering to fund PALSONIFY launch

Crinetics Pharmaceuticals has priced an underwritten public offering of 7.62 million shares of common stock at $45.95 per share, expecting to raise approximately $350 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to an additional 1.14 million shares. The San Diego-based pharmaceutical company, which focuses on treatments for endocrine diseases and endocrine-related tumours, plans to use the net proceeds to fund commercial activities for its recently approved drug PALSONIFY™, research and development of product candidates, and general corporate purposes. The offering is expected to close on 8 January 2026. Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler and Cantor are acting as joint bookrunning managers for the offering.